We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Abbott to Develop Preeclampsia Test

By HospiMedica staff writers
Posted on 02 Aug 2005
Under a recent agreement, worldwide semi-exclusive rights to commercialize products using patents of Nephromics (Chestnut Hill, MA, USA) related to two proteins for detecting and monitoring preeclampsia have been granted to Abbott Laboratories (Abbott Park, IL, USA).

Abbott intends to develop an in vitro diagnostic test to detect preeclampsia. There is currently no specific diagnostic test for this life-threatening disease that affects many pregnant women each year. "Abbott's goal is to develop prenatal tests that could be utilized for early risk stratification of pregnancy complications,” explained William Brown, Ph.D., vice president, diagnostic assays and systems development, Abbott Labs.

Abbott has a history of developing endocrine and other hormone-related tests and offers a broad range of innovative instrument systems and tests across key segments of the global diagnostics market. Immunodiagnostics is a core component of the company's medical products business.

"Because preeclampsia can strike quickly, potentially causing severe and immediate complications such as seizures and organ failure that threaten both the health of the baby and mother unless pregnancy is induced, early diagnostic tests are needed,” observed David Barch, M.D., medical director, Abbott Diagnostics. "These tests would be developed for use on our premier diagnostic analyzer, the Architect integrated immunoassay and clinical chemistry system.”




Related Links:
Abbott
Gold Member
Automated MALDI-TOF MS System
EXS 3000
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Gel Cards
DG Gel Cards

Channels

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
GLOBE SCIENTIFIC, LLC